Vermillion ($VRML) pulled in $17.6 million through the sale of warrants, completing a $31 million equity financing first disclosed in May. The Austin, TX, diagnostics outfit said that Oracle Investment Management, Jack Schuler, Matthew Strobeck and other investors exercised their warrants in the transaction, purchasing 12.1 million shares of common stock at $1.46 per share. The funding will help the company boost sales and reimbursement efforts for Ova1, its pre-surgery algorithmic blood test designed to screen for ovarian cancer. Item